These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2068473)

  • 21. [Pseudomonas aeruginosa infection of the sternum and costal cartilages in cardiosurgery. Therapeutic experience using aztreonam].
    Donegani E; di Summa M; Agaccio G; Comoglio C; De Paulis R; Matani A
    Riv Eur Sci Med Farmacol; 1989 Apr; 11(2):143-8. PubMed ID: 2799000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.
    Retsch-Bogart GZ; Burns JL; Otto KL; Liou TG; McCoy K; Oermann C; Gibson RL;
    Pediatr Pulmonol; 2008 Jan; 43(1):47-58. PubMed ID: 18041081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aztreonam-induced myelosuppression during treatment of Pseudomonas aeruginosa pneumonia.
    Dallal MM; Czachor JS
    DICP; 1991 Jun; 25(6):594-7. PubMed ID: 1877266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
    Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB
    J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aztreonam in the treatment of gram-negative bacterial meningitis.
    Lentnek AL; Williams RR
    Rev Infect Dis; 1991; 13 Suppl 7():S586-90. PubMed ID: 2068463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of aztreonam in pulmonary exacerbations of cystic fibrosis.
    Bosso JA; Black PG; Matsen JM
    Pediatr Infect Dis J; 1987 Apr; 6(4):393-7. PubMed ID: 3588112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of gram-negative peritonitis with aztreonam in patients undergoing continuous ambulatory peritoneal dialysis.
    Dratwa M; Glupczynski Y; Lameire N; Matthys D; Verschraegen G; Vaneechoutte M; Boelaert J; Schurgers M; Van Landuyt H; Verbeelen D
    Rev Infect Dis; 1991; 13 Suppl 7():S645-7. PubMed ID: 2068475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of aztreonam in the treatment of serious gram-negative bacterial infections.
    LeFrock JL; Smith BR; Chandrasekar P; Rolston KV; Molavi A; Kannangara W
    Arch Intern Med; 1987 Feb; 147(2):325-8. PubMed ID: 3813751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical experience with aztreonam.
    Stutman HR
    Pediatr Infect Dis J; 1989 Sep; 8(9 Suppl):S109-12; discussion S128-32. PubMed ID: 2682508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experience with aztreonam in the treatment of gram-negative bacteremia.
    Scully BE; Henry SA
    Rev Infect Dis; 1985; 7 Suppl 4():S789-93. PubMed ID: 3909338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral ciprofloxacin treatment of Pseudomonas aeruginosa osteomyelitis.
    Dan M; Siegman-Igra Y; Pitlik S; Raz R
    Antimicrob Agents Chemother; 1990 May; 34(5):849-52. PubMed ID: 2360823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized comparison of aztreonam and cefuroxime in gram-negative upper urinary tract infections.
    Friman G; Cars O; Bäck E; Beckman H; Carlsson M; Forssell J; Fredlund H; Neringer R; Odenholt-Tornqvist I; Rydén C
    Infection; 1989; 17(5):284-9. PubMed ID: 2689345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of aztreonam in the treatment of neonatal sepsis.
    Sklavunu-Tsurutsoglu S; Gatzola-Karaveli M; Hatziioannidis K; Tsurutsoglu G
    Rev Infect Dis; 1991; 13 Suppl 7():S591-3. PubMed ID: 2068464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis.
    Bosso JA; Black PG
    Pediatr Infect Dis J; 1988 Mar; 7(3):171-6. PubMed ID: 3128767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of aztreonam in the cystic fibrosis patient.
    Matsen JM; Bosso JA
    Pediatr Infect Dis J; 1989 Sep; 8(9 Suppl):S117-9; discussion S128-32. PubMed ID: 2682510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical experience with aztreonam in Germany and Austria.
    Stille W; Gillissen J
    Rev Infect Dis; 1985; 7 Suppl 4():S825-30. PubMed ID: 3909342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infections in patients in intensive care units: can the combination of a monobactam and a penicillin replace the classic combination of a beta-lactam agent and an aminoglycoside?
    Colardyn F; Gala JL; Verschraegen G; Wauters G; Vogelaers D; Dive A; Claeys G; Magis A; Vandercam B; Mahieu P
    Rev Infect Dis; 1991; 13 Suppl 7():S640-4. PubMed ID: 2068474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
    Assael BM
    Expert Rev Anti Infect Ther; 2011 Nov; 9(11):967-73. PubMed ID: 22029514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ticarcillin plus clavulanic acid versus moxalactam therapy of osteomyelitis, septic arthritis, and skin and soft tissue infections.
    Siebert WT; Kopp PE
    Am J Med; 1985 Nov; 79(5B):141-5. PubMed ID: 4073082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prolonged treatment of chronic Pseudomonas aeruginosa osteomyelitis with a combination of two effective antibiotics.
    Lucht RF; Fresard A; Berthelot P; Farizon F; Aubert G; Dorche G; Bousquet G
    Infection; 1994; 22(4):276-80. PubMed ID: 8002088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.